Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab

被引：27

作者：

Clayton, TH ^{[1
]}

Ogden, S ^{[1
]}

Goodfield, MDJ ^{[1
]}

机构：

[1] Leeds Gen Infirm, Dept Dermatol, Leeds LS1 3EX, W Yorkshire, England

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2006年 / 54卷 / 05期

关键词：

D O I：

10.1016/j.jaad.2005.08.025

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

We report the case of a 47-year-old woman who first presented with erythematous plaques on the upper portion of her right arm, which developed into an annular eruption involving the face, upper portion of the trunk, and limbs in a predominantly photosensitive distribution. Findings from histopathologic evaluation of a lesion from her arm were consistent with the clinical diagnosis of SCLE. After years Of unsuccessful treatment with conventional medications for SCLE, she began therapy with efalizumab and experienced dramatic improvement in her cutaneous lesions after 6 weeks.

引用

页码：892 / 895

页数：4

共 21 条

[1]

ABAY C, 1997, J RHEUMATOL, V24, P303

[2] CLOFAZIMINE - A REVIEW OF ITS MEDICAL USES AND MECHANISMS OF ACTION [J].

ARBISER, JL ;

MOSCHELLA, SL .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1995, 32 (02) :241-247

[3] Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus -: An open-label study [J].

Aringer, M ;

Graninger, WB ;

Steiner, GN ;

Smolen, JS .

ARTHRITIS AND RHEUMATISM, 2004, 50 (10) :3161-3169

[4] Increased bioactive TNF in human systemic lupus erythematosus:: associations with cell death [J].

Aringer, M ;

Feierl, E ;

Steiner, G ;

Stummvoll, GH ;

Höfler, E ;

Steiner, CW ;

Radda, I ;

Smolen, JS ;

Graninger, WB .

LUPUS, 2002, 11 (02) :102-108

[5] Serum interleukin-15 is elevated in systemic lupus erythematosus [J].

Aringer, M ;

Stummvoll, GH ;

Steiner, G ;

Köller, M ;

Steiner, CW ;

Höfler, E ;

Hiesberger, H ;

Smolen, JS ;

Graninger, WB .

RHEUMATOLOGY, 2001, 40 (08) :876-881

[6] Etanercept-induced subacute cutaneous lupus erythematosus [J].

Bleumink, GS ;

ter Borg, EJ ;

Ramselaar, CG ;

Stricker, BHC .

RHEUMATOLOGY, 2001, 40 (11) :1317-1319

[7] TREATMENT OF CHRONIC DISCOID LUPUS-ERYTHEMATOSUS WITH AN ORAL GOLD COMPOUND (AURANOFIN) [J].

DALZIEL, K ;

GOING, G ;

CARTWRIGHT, PH ;

MARKS, R ;

BEVERIDGE, GW ;

ROWELL, NR .

BRITISH JOURNAL OF DERMATOLOGY, 1986, 115 (02) :211-216

[8]

DAVIDBAJAR KM, 1995, J INVEST DERMATOL S1, V105, pS71

[9]

Drake LA, 1996, J AM ACAD DERMATOL, V34, P830

[10] Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor α-blocking agent:: Comment on the article by Pisetsky and the letter from Aringer et al [J].

Fautrel, B ;

Foltz, V ;

Frances, C ;

Bourgeois, P ;

Rozenberg, S .

ARTHRITIS AND RHEUMATISM, 2002, 46 (05) :1408-1409

← 1 2 3 →